LSP Life Sciences Fund N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 apr 2011 - 17:40
Statutaire naam
LSP Life Sciences Fund N.V.
Titel
LSP Life Sciences Fund Successfully Raises EUR 36 Million in IPO on NYSE Euronext
Bericht
LSP Life Sciences Fund Successfully Raises EUR 36 Million in IPO on NYSE Euronext
AMSTERDAM--(BUSINESS WIRE)--Regulatory News:
LSP Life Sciences Fund (AEX:LSP), an open-ended fund that invests in publicly listed small- and midcap biotech companies, today announced that it has successfully completed its initial public offering on NYSE Euronext Amsterdam on April 27, raising EUR 36 Million.
“We are very pleased with this initial amount raised in the Fund’s public offering and expect to further grow the Fund in the year ahead by bringing additional investors on board,” said Mark Wegter, co-manager of the Fund.
About the LSP Life Sciences Fund
With a long-term horizon, the Fund will invest in public small- and mid-cap biotech companies, as they offer the greatest potential for value growth. The Fund will specifically target companies that are projected to realize important clinical milestones, commercial partnerships or offer M&A potential to benefit from the significant value increases that usually accompany the announcement of such events. The Fund is an open-end Dutch public company (N.V.) with the status of investment company with variable capital and is an exempt investment institution for Dutch tax purposes. For more information, please go to http://www.lsplifesciencesfund.com.
Contacts
For further enquiries
Mark Wegter
+31 20 664 55 00
mwegter@lspvc.com
or
Joep Muijrers PhD
+31 20 664 55 00
jmuijrers@lspvc.com
Datum laatste update: 01 september 2024